.


:




:

































 

 

 

 


III.




1. .. , ,

2. .. ...,

3. ..- .

4. .. - -

5. .. .

6. .. -

7. ..

 

17. : .

18. :

. , , ..

 

19. : , ,

 

20. :

1. , . .. , 2012.

2. , .., 2011

3. . .2- / . .. . - .: -, 2010. - 738 .

4. .., .., .. ACR/EULAR 2010 //- , 2011, 1, 10-15.

5. . , ., . . / . .. , 2011.

6. Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis withsynthetic and biological disease-modifying antirheumatic drugs. AnnRheumDis, 2010; 69:96475.

7. .. : ( -6). 2010;5:6471.

8. . . 2- ., .., 2010

9. .. () . - 2009; 3(.):1835.

10. Van Vollenhoven R.F. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:53141.

11. .., .., .. . . . .: -, 2009.

12. : / . .. , .. . - .: -, 2008. - 720 .

13. Emery P., Keystone E., Tony H.-P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti- TNF biologics: results from a 24-week multicenter randomized placebo-controlled trial.

14. .. - , 2008

15. AnnRheumDis 2008;67:151623.

16. : ompendium/ .., .., .., .. .; . . .. , .. . .: , 2007. 448.

17. Nam J.L., Wintrop K.L., van Vollenhoven R.F. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systemic literature rewires informing the EULAR recommendationsfor the management of RA.

18. .. () . - , 2009; 3(.):1835.

19. .., .. - , 2007.

20. .. - , 2005.

21. . . . .. - -. , 2001.- .116

22. Paul Emery et al. , , , , ARTHRITIS & RHEUMATISM, 60, 8, 2009, . 22722283, DOI 10.1002/art.24638

23. Mark C. Genovese et al. : GO-FORWARD, J Rheumatol 15 2012 , DOI: 10.3899/jrheum.111195

24. Josef S Smolen ( GO-AFTER): , , , - III, Lancet 2009; 374: 21021

 





:


: 2016-10-23; !; : 581 |


:

:

.
==> ...

1758 - | 1584 -


© 2015-2024 lektsii.org - -

: 0.013 .